Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-06-27
|
mepolizumab |
severe bilateral nasal polyps |
3 |
GSK (UK) |
Inflammatory diseases |
2017-06-27
|
GKT831 (formerly GKT137831) |
primary biliary cholangitis (PBC) |
2 |
Genkyotex (Switzerland) |
Liver diseases - Hepatic diseases |
2017-06-27
|
KL1333 |
genetic mitochondrial diseases |
1 |
Neurovive Pharmaceutical (Sweden) Yungjin Pharm (South Korea) |
Rare diseases - Genetic diseases |
2017-06-26
|
fitusiran (SAR439774 - ALN-AT3) |
hemophilia A |
preclinical |
Alnylam Pharmaceuticals (USA - MA) |
Hematological diseases - Genetic diseases - Rare diseases |
2017-06-26
|
givosiran (ALN-AS1) |
acute hepatic porphyria |
observational |
Alnylam Pharmaceuticals (USA - MA) |
Rare diseases - Metabolic diseases |
2017-06-26
|
ALN-F12 |
hereditary angioedema, prevention of thrombosis |
preclinical |
Alnylam Therapeutics (USA - MA) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-06-26
|
CB 2679d/ISU304 |
hemophilia B |
preclinical |
Catalyst Biosciences (USA - CA) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-06-25
|
CD44v6 CAR-T cells |
|
preclinical |
Molmed (Italy) |
Cancer - Oncology |
2017-06-24
|
Idhifa® (enasidenib) |
relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation |
1-2 |
Celgene (USA - NJ) Agios Pharmaceuticals (USA -MA) |
Cancer - Oncology |
2017-06-24
|
AG-348 |
pyruvate kinase deficiency |
2 |
Agios Pharmaceuticals (USA -MA) |
Rare diseases - Genetic diseases |
2017-06-23
|
CTL019 - tisagenlecleucel-T |
B-cell acute lymphoblastic leukemia |
2 |
Novartis (Switzerland) |
Cancer - Oncology |
2017-06-23
|
Ocrevus® (ocrelizumab) |
relapsing multiple sclerosis (RMS) primary progressive multiple sclerosis (PPMS) |
3 |
Genentech, a member of Roche Group (USA - CA - Switzerland) |
Autoimmune diseases - Neurodegenerative diseases |
2017-06-23
|
Rydapt®(midostaurin) |
newly diagnosed FLT3-mutated acute myeloid leukemia (AML) |
3 |
Novartis (Switzerland) |
Cancer - Oncology |
2017-06-22
|
dasiglucagon (ZP4207) and bionic pancreas |
type 1 diabetes |
2a |
Zealand Pharma (Denmark) Beta Bionics (USA - MA) |
Metabolic diseases |
2017-06-20
|
IVA337 - lanifibranor- 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid) |
NASH (non-alcoholic steatohepatitis) |
preclinical |
Inventiva Pharma (France) |
Liver diseases - Hepatic diseases |
2017-06-19
|
SGN-CD33A (vadastuximab talirine) in combination with azacitidine (Vidaza®) |
myelodysplastic syndrome |
1-2 |
Seattle Genetics (USA - WA) |
Cancer - Oncology |
2017-06-19
|
vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine |
acute myeloid leukemia |
3 |
Seattle Genetics (USA - WA) |
Cancer - Oncology |
2017-06-17
|
Truxima® (CT-P10 - biosimilar rituximab - biosimilar version of Mabthera®/Rituxan® ) |
advanced follicular lymphoma, rheumatoid arthritis |
|
Celltrion Healthcare (South Korea) |
Cancer - Oncology - Autoimmune diseases - Rheumatic diseases |
2017-06-17
|
MGD010 |
autoimmune diseases |
1 |
Macrogenics (USA - MD) |
Autoimmune diseases |
2017-06-16
|
ixekizumab |
active psoriatic arthritis |
3 |
Eli Lilly (USA - IN) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |